This year, his name appeared for the first time on the list of "Highly Cited Researchers 2020" compiled by Clarivate Analytics. This list includes scientists whose publications were among the "top 1 percent" based on the numbers of citations from 2009-2019. How often scientific publications are cited by peers is considered an indicator of a researcher's influence. The list, published in November, includes about 6,000 scientists from more than 60 countries.

Prof. Haberkorn's research group investigates how radioactive molecules can be used to diagnose and treat malignant tumors and  develops new radioactively labeled drugs (radiopharmaceuticals). Among the most cited publications in the last decade were four papers on the development, clinical introduction and validation of a radiopharmaceutical (PSMA-HBEDCC or PSMA-11) that binds to the prostate-specific membrane protein (PSMA). These publications have been cited by peers approximately 2000 times to date.

The latest radiopharmaceutical developed by the research group is called 68Ga-FAPI and is used, among other things, to diagnose lung cancer and pulmonary fibrosis. It binds specifically to the enzyme FAP (fibroblast activation protein), which is predominantly found on cancer-associated connective tissue cells and on fibrosed tissue. One of the publications on this topic was selected as the best clinical article of 2019 by the Journal of Nuclear Medicine. This and another publication on this topic were among the most cited articles in the journal over the past two years.

/ TLRC - Doreen Penso Dolfin

Further information:

Publications of Prof. Uwe Ha­ber­korn

High­ly Cited Re­se­ar­chers 2020